Drugs / ^90Y-DOTA-cG250
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00199875 | Jul 2005 → Mar 2013 | renal cell carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ^90Y-DOTA-cG250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00199875 ↗ |
| Modality | Monoclonal antibody | “Chimeric Monoclonal Antibody cG250” NCT00199875 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT00199875 ↗ |